HumaCare Publicaties - Met HumaCare kunt u gebruiksvriendelijk en in alle privacy een HPV thuistest uitvoeren

Publicaties

1. "The epidemiology of human papillomavirus infections".

Baseman JG, Koutsky LA.
"The epidemiology of human papillomavirus infections".
J Clin Virol 2005 Mar;32 Suppl 1:S16-24.

2. "A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine".

Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E.
"A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine".
Int J Cancer. 2003 Oct 10;106(6):896-904.

3. "The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women".

Carter JJ, Koutsky LA, Wipf GC, et al.
"The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women".
J Infect Dis. 1996 Nov;174(5):927-36.

4. "Human Papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance".

van Duin M, Snijders P, Schrijnemakers, et al.
"Human Papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance".
Int J Cancer: 98, 590-595.

5. "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial".

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM,Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group.
"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial".
Lancet. 2006 Apr 15;367(9518):1247-55.

6. "GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial".

Harper DM, Franco EL, Wheeler C, et al.
"GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial".
Lancet. 2004 Nov 13;364(9447):1757-6.

7. "Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6".

de Jong A, van Poelgeest MI, van der Hulst JM, et al.
"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6".
Cancer Res. 2004 Aug 1;64(15):5449-55.

8. "A controlled trial of a human papillomavirus type 16 vaccine".

"A controlled trial of a human papillomavirus type 16 vaccine".
Koutsky LA, Ault KA, Wheeler CM, et al. Proof of Principle Study Investigators.
N Engl J Med. 2002 Nov 21;347(21):1645-51.

9. "Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study".

"Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study".
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ.
Lancet 1999 Jul 3; 354(9172):20-5.

10. "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial".

"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial".
Villa LL, Costa RIR, Petta CA, et al.
Lancet Oncology 2005.

11. "High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up".

"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up".
Villa LL, Costa RIR, Petta CA, et al.
Brit J Cancer 2006: 95: 1459-1466.

12. "Vaccinatie tegen Humaan Papillomavirus ter preventie van baarmoederhalskanker".

"Vaccinatie tegen Humaan Papillomavirus ter preventie van baarmoederhalskanker".
W.G.V. Quint, W.A. ter Harmsel en L.J. van Doorn.
Ned Tijdschr Geneeskd. 2006;150:1380-4.

Volg HumaCare